N

New Phase Research & Development | Knoxville, TN

Research site

(Unclaimed)

Location

6914 Office Park Circle, Knoxville, Tennessee, United States of America

Site insights

Top conditions

Top treatments

LY3298176

Ranolazine

Tirzepatide

Testosterone

Metformin

Bococizumab

MD-7246

Capsaicin

Loperamide

RPL554

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 41 total trials

A Study to Evaluate Solrikitug in Participants With COPD (ZION)

A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic...

Active, not recruiting

COPD

Other: Placebo

Biological: Biological: Solrikitug high dose

A Study to Evaluate Solriktug in Adult Participants With Asthma (RAINIER)

Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.

Active, not recruiting

Asthma

Biological: NSI-8226

Biological: Placebo

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (PREVAIL)

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Obicetrapib

Drug: Placebo

Status recently updated

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to...

Not yet enrolling

Enrolling

Overweight

Obesity

Drug: ABBV-295

Drug: Placebo